SCHEMBL5118318

SCHEMBL5118318

CCCN(CCC)C(=O)c1cc(C(=O)O)cc(S(=O)(=O)NCCO)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.53
TLR8 Q9NR97 2/20 0.43
CYP1A2 P05177 1/20 0.42
NTRK2 Q16620 1/20 0.42
LIMK1 P53667 2/20 0.40
AKR1C3 P42330 6/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
MEP1B Q16820 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CA9 Q16790 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
SLC22A8 Q8TCC7 1/20 0.38
ABCC2 Q92887 1/20 0.38
SLC22A12 Q96S37 1/20 0.38
UGT1A7 Q9HAW7 1/20 0.38
SLC22A11 Q9NSA0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5124899 0.92 CYP2C19 (0.44) CYP2C19TLR8CYP1A2NTRK2LIMK1
Hydrochloric Acid SCHEMBL5130464 0.88 CYP1A2 (0.40) CYP2C19CYP1A2LIMK1AKR1C3RAB9A
SCHEMBL7608105 0.84 CYP1A2 (0.46) CYP1A2LIMK1RAB9ANPC1CA12
SCHEMBL5124718 0.80 CYP2C19 (0.56) CYP2C19CYP1A2NTRK2AKR1C3MEP1B
SCHEMBL13306191 0.80 NTRK2 (0.41) CYP1A2NTRK2LIMK1RAB9ACA12
SCHEMBL27613909 0.79 CA2 (0.48) CYP2C19TLR8CYP1A2LIMK1RAB9A
SCHEMBL7115213 0.74 MLYCD (0.43) NTRK2PKM
SCHEMBL2953707 0.73 TPMT (0.53) SMN1; SMN2
SCHEMBL3886133 0.73 MLYCD (0.45) NTRK2RAB9ANPC1ALDH1A1CA12
SCHEMBL14376244 0.73 CA12 (0.50) RAB9AALDH1A1CA12CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 CYP2C19 2654/4885TLR8 4878/4885CYP1A2 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.